Skip to main content

Chemoembolization clinical trials at UCSF
1 in progress, 0 open to eligible people

  • TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

    Sorry, accepting new patients by invitation only

    TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. The purpose of the study is to determine whether transarterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction.

    San Francisco, California

Last updated: